Abstract
Disease progression and drug response may vary significantly from patient to patient. Fortunately, the rapid development of high-throughput 'omics' technologies has allowed for the identification of potential biomarkers that may aid in the understanding of the heterogeneities in disease development and treatment outcomes. However, mechanistic gaps remain when the genome or the proteome are investigated independently in response to drug treatment. In this article, we discuss the current status of pharmacogenomics in precision medicine and highlight the needs for concordant analysis at the proteome and metabolome levels via the more recently-evolved fields of pharmacoproteomics, toxicoproteomics, and pharmacometabolomics. Integrated 'omics' investigations will be critical in piecing together targetable mechanisms of action for both drug development and monitoring of therapy in order to fully apply precision medicine to the clinic.
Keywords
PharmacogenomicsPrecision medicineProteomeOmicsDrug developmentMetabolomeDiseaseProteomicsComputational biologyDrug responseIdentification (biology)Personalized medicineMedicineBioinformaticsDrug discoveryData scienceDrugComputer scienceBiologyPharmacologyMetabolomicsInternal medicinePathologyGenetics
Affiliated Institutions
Related Publications
Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine
The scaling up of data in clinical pharmacology and the merger of systems biology and pharmacology has led to the emergence of a new discipline of Quantitative and Systems Pharm...
Pharmacogenomics: a systems approach
Abstract Pharmacogenetics and pharmacogenomics involve the study of the role of inheritance in individual variation in drug response, a phenotype that varies from potentially li...
DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
DrugBank (http://www.drugbank.ca) is a richly annotated database of drug and drug target information. It contains extensive data on the nomenclature, ontology, chemistry, struct...
Characterization and quantitation of membrane proteomes using multidimensional MS-based proteomic technologies
A major goal of proteomics is to develop methods that enable the systematic characterization of every protein within the cell or particular subcellular proteome using a single a...
MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis
We present a new update to MetaboAnalyst (version 4.0) for comprehensive metabolomic data analysis, interpretation, and integration with other omics data. Since the last major u...
Publication Info
- Year
- 2016
- Type
- review
- Volume
- 13
- Issue
- 1
- Pages
- 25-25
- Citations
- 49
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
49
OpenAlex
Cite This
Allison B Chambliss,
Daniel W. Chan
(2016).
Precision medicine: from pharmacogenomics to pharmacoproteomics.
Clinical Proteomics
, 13
(1)
, 25-25.
https://doi.org/10.1186/s12014-016-9127-8
Identifiers
- DOI
- 10.1186/s12014-016-9127-8